Adolfo Garcia Ocana, PhD Email Adolfo Garcia Ocana
-
- Position
- PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
-
- Language
- English
Dr. Garcia-Ocaña’s research interest has focused over the years on tissue regeneration, growth factors and intracellular signaling. More specifically, his group is analyzing the therapeutic potential of growth promoting agents to induce pancreatic beta cell regeneration in diabetes. He described for the first time that expression of hepatocyte growth factor (HGF) in vivo in the beta cell markedly increases beta cell proliferation, survival, function and mass in transgenic mice. In addition, he also demonstrated the beneficial effects of HGF on improving islet transplant outcomes. These novel results highlighted the potential of growth factors, and in particular HGF, for beta cell regeneration and replacement therapies in diabetes.
His group has also identified the intracellular signaling pathways involved in the beneficial effects of growth factors in beta cells. They have found that the Akt pathway is required for the anti-apoptotic effects of HGF and that activation of this pathway is enough to improve long-term human islet engraftment and survival in mice without adverse effects. They have also found that protein kinase C (PKC) ζ is a key and novel signaling pathway involved in growth factor-induced beta cell replication. Activation of PKC ζ leads to markedly increased rodent beta cell expansion and more importantly human beta cell replication. In addition, activation of PKC ζ enhances insulin expression and secretion. These findings highlight this pathway as an attractive target for beta cell regeneration.
Recently, he has also centered his interest on the physiological roles of HGF and PKC ζ in the beta cell. Using genetically-modified mouse models, he has shown that the absence of HGF sgnaling in beta cells leads to the development of gestational diabetes. These results open the door to important translational studies in pregnant women with gestational diabetes, an aspect currently being explored by Dr. Garcia-Ocana in collaboration with Dr. Carol Levy. We believe that the knowledge obtained from these studies can lead to the development of future effective therapies to increase beta cell regeneration, to improve beta cell replacement and to expand beta cell mass for diabetes.
Research Topic
Apoptosis/Cell Death, Cell Biology, Cell Cycle, Cell Division, Diabetes, Gene Expressions, Gene Regulation, Gene Therapy, Growth Factors and Receptors, Hormones, Knockout Mice, Molecular Biology, Obesity, Protein Kinases, Receptors, Signal Transduction, Transcription Factors, Transgenic Mice, Transplantation
Multi-Disciplinary Training Area
Pharmacology and Therapeutics Discovery [PTD]
Education
BS, Universidad Autonoma of Madrid
PhD, Universidad Autonoma of Madrid
PhD Student, Université Paris VII, Dept. of Renal Physiology, Faculté de Medecine Xavier Bichat
Language
English
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Garcia Ocana did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.